Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events

American Journal of Cardiology

Volumn 111, Issue 8, 2013, Pages 1221-1229

  Larosa, John C ^a   Pedersen, Terje R ^b   Somaratne, Ransi ^c   Wasserman, Scott M ^c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BRAIN HEMORRHAGE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; REVIEW;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 84875847301     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.12.052     Document Type: Review

References (78)

1. K.M. Anderson, W.P. Castelli, and D. Levy Cholesterol and mortality: 30 years of follow-up from the Framingham study JAMA 257 1987 2176 2180
2. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis, and E. Braunwald The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators N Engl J Med 335 1996 1001 1009
3. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, J.H. McKillop, and C.J. Packard Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
5. T.R. Pedersen, O. Faergeman, J.J. Kastelein, A.G. Olsson, M.J. Tikkanen, I. Holme, M.L. Larsen, F.S. Bendiksen, C. Lindahl, M. Szarek, J. Tsai Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
6. P.M. Ridker, E. Danielson, F.A. Fonseca, J. Genest, A.M. Gotto Jr., J.J. Kastelein, W. Koenig, P. Libby, A.J. Lorenzatti, J.G. MacFadyen, B.G. Nordestgaard, J. Shepherd, J.T. Willerson, R.J. Glynn, and J.S. Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
7. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, and N.K. Wenger Treating to new targets: I. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
8. R.R. Giraldez, R.P. Giugliano, S. Mohanavelu, S.A. Murphy, C.H. McCabe, C.P. Cannon, and E. Braunwald Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis J Am Coll Cardiol 52 2008 914 920
9. V. Ramjee, and T.A. Jacobson Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old Clin Lipidol 6 2011 131 136
10. C.R. Parker Jr., B.R. Carr, E.R. Simpson, and P.C. MacDonald Decline in the concentration of low-density lipoprotein-cholesterol in human fetal plasma near term Metabolism 32 1983 919 923
11. J.M. Dietschy, and S.D. Turley Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal J Lipid Res 45 2004 1375 1397
12. W.W. Wong, D.L. Hachey, W. Insull, A.R. Opekun, and P.D. Klein Effect of dietary cholesterol on cholesterol synthesis in breast-fed and formula-fed infants J Lipid Res 34 1993 1403 1411
13. T.B. Hickman, R.R. Briefel, M.D. Carroll, B.M. Rifkind, J.I. Cleeman, K.R. Maurer, and C.L. Johnson Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey Prev Med 27 1998 879 890
14. J.D. Cohen, M.J. Cziraky, Q. Cai, A. Wallace, T. Wasser, J.R. Crouse, and T.A. Jacobson 30-Year trends in serum lipids among United States adults: results from the National Health and Nutrition Examination Surveys II, III, and 1999-2006 Am J Cardiol 106 2010 969 975
15. J.W. Kemnitz, R.M. Sapolsky, J. Altmann, P. Muruthi, G.E. Mott, and M.L. Stefanick Effects of food availability on serum insulin and lipid concentrations in free-ranging baboons Am J Primatol 57 2002 13 19
16. E.S. Ford, C. Li, G. Zhao, and A.H. Mokdad Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States Circulation 119 2009 1108 1115
17. M.J. Martin, S.B. Hulley, W.S. Browner, L.H. Kuller, and D. Wentworth Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men Lancet 2 1986 933 936
18. F.A. Jaffer, C.J. O'Donnell, M.G. Larson, S.K. Chan, K.V. Kissinger, M.J. Kupka, C. Salton, R.M. Botnar, D. Levy, and W.J. Manning Age and sex distribution of subclinical aortic atherosclerosis: a magnetic resonance imaging examination of the Framingham Heart Study Arterioscler Thromb Vasc Biol 22 2002 849 854
19. W. Hochholzer, and R.P. Giugliano Lipid lowering goals: back to nature? Ther Adv Cardiovasc Dis 4 2010 185 191
20. N. Mann Dietary lean red meat and human evolution Eur J Nutr 39 2000 71 79
21. S.G. De Biase, S.F. Fernandes, R.J. Gianini, and J.L. Duarte Vegetarian diet and cholesterol and triglycerides levels Arq Bras Cardiol 88 2007 35 39
22. J.H. O'Keefe Jr., L. Cordain, W.H. Harris, R.M. Moe, and R. Vogel Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal J Am Coll Cardiol 43 2004 2142 2146
23. M.P. McMurry, M.T. Cerqueira, S.L. Connor, and W.E. Connor Changes in lipid and lipoprotein levels and body weight in Tarahumara Indians after consumption of an affluent diet N Engl J Med 325 1991 1704 1708
24. T. Munch-Andersen, D.B. Olsen, H. Søndergaard, J.R. Daugaard, A. Bysted, D.L. Christensen, B. Saltin, and J.W. Helge Metabolic profile in two physically active Inuit groups consuming either a western or a traditional Inuit diet Int J Circumpolar Health 71 2012 E1 E8
25. Z. Chen, R. Peto, R. Collins, S. MacMahon, J. Lu, and W. Li Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations BMJ 303 1991 276 282
26. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. MacFarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, and R.G. Westendorp Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
27. T. Gordon, W.B. Kannel, W.P. Castelli, and T.R. Dawber Lipoproteins, cardiovascular disease, and death: the Framingham study Arch Intern Med 141 1981 1128 1131
28. H. Iso, D.R. Jacobs Jr., D. Wentworth, J.D. Neaton, and J.D. Cohen Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial N Engl J Med 320 1989 904 910
29. P. Amarenco, J. Bogousslavsky, A. Callahan III, L.B. Goldstein, M. Hennerici, A.E. Rudolph, H. Sillesen, L. Simunovic, M. Szarek, K.M. Welch, J.A. Zivin Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
30. N.J. Wald, S.G. Thompson, M.R. Law, J.W. Densem, and A. Bailey Serum cholesterol and subsequent risk of cancer: results from the BUPA study Br J Cancer 59 1989 936 938
31. M.R. Law, and S.G. Thompson Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies Cancer Causes Control 2 1991 253 261
32. M.R. Law, S.G. Thompson, and N.J. Wald Assessing possible hazards of reducing serum cholesterol BMJ 308 1994 373 379
33. F.H. Epstein Low serum cholesterol, cancer and other noncardiovascular disorders Atherosclerosis 94 1992 1 12
34. J. Ahn, U. Lim, S.J. Weinstein, A. Schatzkin, R.B. Hayes, J. Virtamo, and D. Albanes Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer Cancer Epidemiol Biomarkers Prev 18 2009 2814 2821
35. A.M. Strasak, R.M. Pfeiffer, L.J. Brant, K. Rapp, W. Hilbe, W. Oberaigner, S. Lang, W. Borena, H. Concin, G. Diem, E. Ruttmann, B. Glodny, K.P. Pfeiffer, H. Ulmer VHM&PP Study Group Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study Ann Oncol 20 2009 1113 1120
36. H. Iso, A. Ikeda, M. Inoue, S. Sato, S. Tsugane, and J.S. Group Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts Int J Cancer 125 2009 2679 2686
37. E.A. Platz, C. Till, P.J. Goodman, H.L. Parnes, W.D. Figg, D. Albanes, M.L. Neuhouser, E.A. Klein, I.M. Thompson Jr., and A.R. Kristal Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial Cancer Epidemiol Biomarkers Prev 18 2009 2807 2813
38. W.H. Ettinger, L.D. Miller, J.J. Albers, T.K. Smith, and J.S. Parks Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys J Lipid Res 31 1990 1099 1107
39. S. Vitols, G. Gahrton, M. Bjorkholm, and C. Peterson Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia Lancet 2 1985 1150 1154
40. J.A. Cauley, A. McTiernan, R.J. Rodabough, A. LaCroix, D.C. Bauer, K.L. Margolis, E.D. Paskett, M.Z. Vitolins, C.D. Furberg, R.T. Chlebowski Women's Health Initiative Research Group Statin use and breast cancer: prospective results from the Women's Health Initiative J Natl Cancer Inst 98 2006 700 707
41. S. Setoguchi, R.J. Glynn, J. Avorn, H. Mogun, and S. Schneeweiss Statins and the risk of lung, breast, and colorectal cancer in the elderly Circulation 115 2007 27 33
42. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, J. Emberson, L.E. Holland, C. Reith, N. Bhala, R. Peto, E.H. Barnes, A. Keech, J. Simes, and R. Collins Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
43. J.R. Emberson, P.M. Kearney, L. Blackwell, C. Newman, C. Reith, N. Bhala, L. Holland, R. Peto, A. Keech, R. Collins, J. Simes, and C. Baigent Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy PLoS ONE 7 2012 e29849
44. I. Karp, H. Behlouli, J. Lelorier, and L. Pilote Statins and cancer risk Am J Med 121 2008 302 309
45. N.J. Samadder, B. Mukherjee, S.C. Huang, J. Ahn, H.S. Rennert, J.K. Greenson, G. Rennert, and S.B. Gruber Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use Cancer 117 2011 1640 1648
46. S. Nielsen, B.G. Nordestgaard, and S. Bojesen Statin use and reduced cancer-related mortality N Engl J Med 367 2012 1792 1802
47. L.B. Goldstein, P. Amarenco, M. Szarek, A. Callahan III, M. Hennerici, H. Sillesen, J.A. Zivin, and K.M. Welch Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study Neurology 70 2008 2364 2370
48. J. Hsia, J.G. MacFadyen, J. Monyak, and P.M. Ridker Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol 57 2011 1666 1675
49. N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J. de Craen, S.R. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T.R. Pedersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K.K. Ray, and I. Ford Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
50. D. Preiss, S.R. Seshasai, P. Welsh, S.A. Murphy, J.E. Ho, D.D. Waters, D.A. DeMicco, P. Barter, C.P. Cannon, M.S. Sabatine, E. Braunwald, J.J. Kastelein, J.A. de Lemos, M.A. Blazing, T.R. Pedersen, M.J. Tikkanen, N. Sattar, and K.K. Ray Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
51. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 571
52. K. Brusgaard, L. Kjaersgaard, A.B. Hansen, and S. Husby New mutations in APOB100 involved in familial hypobetalipoproteinemia J Clin Lipidol 4 2010 181 184
53. E. Moutzouri, M. Elisaf, and E.N. Liberopoulos Hypocholesterolemia Curr Vasc Pharmacol 9 2011 200 212
54. C. Gutierrez-Cirlos, M.L. Ordonez-Sanchez, M.T. Tusie-Luna, B.W. Patterson, G. Schonfeld, and C.A. Aguilar-Salinas Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease Ann Hepatol 10 2011 155 164
55. M.F. Linton, R.V. Farese Jr., and S.G. Young Familial hypobetalipoproteinemia J Lipid Res 34 1993 521 541
56. P. Tarugi, and M. Averna Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum Adv Clin Chem 54 2011 81 107
57. R.R. Sankatsing, S.W. Fouchier, S. de Haan, B.A. Hutten, E. de Groot, J.J. Kastelein, and E.S. Stroes Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia Arterioscler Thromb Vasc Biol 25 2005 1979 1984
58. A. Gangloff, J. Bergeron, P. Couture, R. Martins, R.A. Hegele, and C. Gagne A novel mutation of apolipoprotein B in a French Canadian family with homozygous hypobetalipoproteinemia J Clin Lipidol 5 2011 414 417
59. C.J. Glueck, W. Kelley, A. Gupta, R.N. Fontaine, P. Wang, and P.S. Gartside Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I Metabolism 46 1997 625 633
60. S.W. Park, Y.A. Moon, and J.D. Horton Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver J Biol Chem 279 2004 50630 50638
61. K.N. Maxwell, and J.L. Breslow Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype Proc Natl Acad Sci U S A 101 2004 7100 7105
62. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
63. Z. Zhao, Y. Tuakli-Wosornu, T.A. Lagace, L. Kinch, N.V. Grishin, J.D. Horton, J.C. Cohen, and H.H. Hobbs Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 2006 514 523
64. B. Cariou, K. Ouguerram, Y. Zair, R. Guerois, C. Langhi, S. Kourimate, I. Benoit, C. Le May, C. Gayet, K. Belabbas, F. Dufernez, M. Chetiveaux, P. Tarugi, M. Krempf, P. Benlian, and P. Costet PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia Arterioscler Thromb Vasc Biol 29 2009 2191 2197
65. A. Roubtsova, M.N. Munkonda, Z. Awan, J. Marcinkiewicz, A. Chamberland, C. Lazure, K. Cianflone, N.G. Seidah, and A. Prat Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue Arterioscler Thromb Vasc Biol 31 2011 785 791
66. R. Zamel, R. Khan, R.L. Pollex, and R.A. Hegele Abetalipoproteinemia: two case reports and literature review Orphanet J Rare Dis 3 2008 19
67. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 1998 1349 1357
68. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
69. D.D. Waters, J.R. Guyton, D.M. Herrington, M.P. McGowan, N.K. Wenger, and C. Shear Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93 2004 154 158
70. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
71. J. Armitage, L. Bowman, K. Wallendszus, R. Bulbulia, K. Rahimi, R. Haynes, S. Parish, R. Peto, and R. Collins Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
72. J.A. de Lemos, M.A. Blazing, S.D. Wiviott, E.F. Lewis, K.A. Fox, H.D. White, J.L. Rouleau, T.R. Pedersen, L.H. Gardner, R. Mukherjee, K.E. Ramsey, J. Palmisano, D.W. Bilheimer, M.A. Pfeffer, R.M. Califf, and E. Braunwald Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
73. B.K. Kim, D.W. Kim, S. Oh, S.J. Yoon, S. Park, D.W. Jeon, and J.Y. Yang Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents Coron Artery Dis 21 2010 182 188
74. J.C. LaRosa, S.M. Grundy, J.J. Kastelein, J.B. Kostis, H. Greten Treating to New Targets (TNT) Steering Committee and Investigators Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study) Am J Cardiol 100 2007 747 752
75. S.D. Wiviott, C.P. Cannon, D.A. Morrow, K.K. Ray, M.A. Pfeffer, E. Braunwald, and PROVE IT-TIMI 22 Investigators Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy J Am Coll Cardiol 46 2005 1411 1416
76. T.T. Tsai, B.K. Nallamothu, D. Mukherjee, M. Rubenfire, J. Fang, P. Chan, E. Kline-Rogers, A. Patel, D.F. Armstrong, K.A. Eagle, and A.D. Goldberg Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein
77. N.J. Leeper, R. Ardehali, E.M. deGoma, and P.A. Heidenreich Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival Circulation 116 2007 613 618
78. K.H. Lee, M.H. Jeong, H.M. Kim, Y. Ahn, J.H. Kim, S.C. Chae, Y.J. Kim, S.H. Hur, I.W. Seong, T.J. Hong, D.H. Choi, M.C. Cho, C.J. Kim, K.B. Seung, W.S. Chung, Y.S. Jang, S.W. Rha, J.H. Bae, J.G. Cho, and S.J. Park Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol J Am Coll Cardiol 58 2011 1664 1671